

12th May 2025

ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine" or the "Company")

Ondine Biomedical Joins CAN Health Network to Advance its Innovation in Infection Prevention Across Canada

Membership provides strategic support, insights and connections as Ondine works to scale its infection prevention technology.

Ondine Biomedical Inc. (LON: OBI) is pleased to announce its membership with the CAN Health Network - a national initiative focused on accelerating the adoption of Canadian technology within the health care system. Through this membership, Ondine becomes part of a growing network of Canadian companies that are working to address some of the sector's most complex challenges with homegrown solutions.

As a member of the Network, Ondine will have access to strategic connections, tailored support, and valuable market insights to help advance the adoption of its innovative Steriwave[®] technology. This opportunity reflects Ondine's ongoing commitment to improving health outcomes and contributing to a stronger, more resilient Canadian health care system.

The CAN Health Network, a federally funded organization, is dedicated to scaling Canadian healthcare innovation companies by connecting them with healthcare operators nationwide. CAN Health facilitates the rapid commercialization and widespread adoption of Canadian-made solutions, enabling companies like Ondine to expand their reach and impact both domestically and in global markets.

Carolyn Cross, CEO of Ondine Biomedical stated:

"Ondine Biomedical is proud to join the CAN Health Network. This membership provides us with valuable opportunities to collaborate with Canada's foremost healthcare innovators and further our goal of expanding access to Steriwave and delivering enhanced patient outcomes across the country."

Ondine's Steriwave nasal photodisinfection offers a transformative approach to infection prevention. This proprietary, light-activated antimicrobial rapidly eliminates pathogens, including multidrug-resistant strains, without contributing to the growing crisis of drug resistance.

Steriwave has demonstrated significant reductions in post-surgical infections and impressive cost savings in both Canadian and UK hospitals. A 14-year study led by Professor John Street, Director of the Integrated Ambulatory Spine program at Vancouver General Hospital, showed a 66.5% reduction in spine surgery infections, prompting the study authors to recommend nasal photodisinfection as the standard of care for all spine surgeries. At Mid Yorkshire NHS Teaching Trust in the UK, Steriwave achieved a 70% reduction in the rate of knee and hip infections compared to a standard of care protocol that included a topical nasal gel. Separately, a study by the York Health Economics Consortium (YHEC) suggests that widespread adoption of Steriwave could save UK hospitals up to £200 million annually by reducing surgical-site infections.

Professor John Street has stated:

"In my opinion, there have been very few if any other initiatives that have had such a profound and lasting impact on the health of British Columbians in the past 10 years."

Enquiries:

Ondine Biomedical Inc.

Carolyn Cross, CEO

www.ondinebio.com

+1 604 669 0555

or via Vane Percy & Roberts

Strand Hanson Limited (Nominated & Financial Adviser)

James Harris, Richard Johnson

+44 (0)20 7409 3494

RBC Capital Markets (Broker)

Kathryn Deegan

+44 (0)20 7653 4000

Vane Percy & Roberts (Media Contact)

Simon Vane Percy, Amanda Bernard

+44 (0)77 1000 5910

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies (photodisinfection) for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is approved in Canada, Australia, Mexico and several other countries under the name Steriwave[®]. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.

About CAN Health Network

The CAN Health Network is a federally funded, national organization accelerating the adoption of Canadian innovation within the health care system. The Network partners leading Canadian health care providers-known as Edges-with homegrown technology companies to validate, procure, and scale their solutions across Canada and beyond. By breaking down traditional barriers to entry, CAN Health is helping Canadian companies grow while strengthening the health care system. Learn more at canhealthnetwork.ca.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAGPUQUAUPAGAG